Literature DB >> 29653177

Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system.

Azmat Ali Khan1, Amer M Alanazi2, Mumtaz Jabeen3, Shahanavaj Khan4, Abdul Malik5.   

Abstract

Cryptococcus neoformans is one of the most lethal fungi causing mortality across the globe. Immuno-competent patients and patients taking immuno-suppressive medications are extremely susceptible to its infection. For effective removal of cryptococcal burden, there is an urgent need for new forms of therapy. In the present study, we have explored the potential effects of amphotericin B (AMB) and fluconazole (FLC) in combination, against cryptococcosis in Swiss albino mice. To enhance the therapeutic potential of the tested drugs, they were entrapped into fibrin microspheres; a dual delivery vehicle comprising of poly-lactide co-glycolide (PLGA) microsphere that was additionally encapsulated into the fibrin cross-linked plasma bead. Dynamics of fibrin microspheres included survival and fungal burden in lung, liver and spleen of treated mice. While each drug was effective in combination or alone, prominent additive potential of AMB and FLC were clearly observed when used in fibrin microsphere. Significant reduction in fungal burden and increase in survival rate of AMB + FLC-fibrin microspheres treated mice shows an extensive accessibility of both tested drugs without any side-effects. A full potential of two-drug combination encapsulated in fibrin microspheres proposes an effective approach of safe delivery to the target site in their intact form and decrease the drug associated toxicities.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Combination therapy; Cryptococcus neoformans; Dual delivery; Fibrin microspheres; PLGA microspheres

Mesh:

Substances:

Year:  2018        PMID: 29653177     DOI: 10.1016/j.ejps.2018.04.015

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Increase of reactive oxygen species contributes to growth inhibition by fluconazole in Cryptococcus neoformans.

Authors:  Nadir Hani Dbouk; Madison Bailey Covington; Kenny Nguyen; Srikripa Chandrasekaran
Journal:  BMC Microbiol       Date:  2019-11-06       Impact factor: 3.605

2.  Joining forces: Leveraging novel combination therapies to combat infections with eukaryotic pathogens.

Authors:  Rachel E Ham; Lesly A Temesvari
Journal:  PLoS Pathog       Date:  2020-12-31       Impact factor: 6.823

Review 3.  Combination Therapy to Treat Fungal Biofilm-Based Infections.

Authors:  Jana Tits; Bruno P A Cammue; Karin Thevissen
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

4.  Enhanced Efficacy of Thiosemicarbazone Derivative-Encapsulated Fibrin Liposomes against Candidiasis in Murine Model.

Authors:  Azmat Ali Khan; Amer M Alanazi; Nawaf Alsaif; Nasser Algrain; Tanveer Ahmad Wani; Mashooq Ahmad Bhat
Journal:  Pharmaceutics       Date:  2021-03-04       Impact factor: 6.321

5.  Resorbable Beads Provide Extended Release of Antifungal Medication: In Vitro and In Vivo Analyses.

Authors:  Yung-Heng Hsu; Huang-Yu Chen; Jin-Chung Chen; Yi-Hsun Yu; Ying-Chao Chou; Steve Wen-Neng Ueng; Shih-Jung Liu
Journal:  Pharmaceutics       Date:  2019-10-24       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.